首页 > 最新文献

Arthritis Research & Therapy最新文献

英文 中文
Gout-associated SNP at the IL1RN-IL1F10 region is associated with altered cytokine production in PBMCs of patients with gout and controls 痛风相关 SNP(位于 IL1RN-IL1F10 区域)与痛风患者和对照组 PBMC 中细胞因子分泌的改变有关
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-20 DOI: 10.1186/s13075-024-03436-0
Orsolya I. Gaal, Megan Leask, Valentin Nica, Georgiana Cabău, Medeea Badii, Ioana Hotea, Dennis M de Graaf, Zhenhua Zhang, Yang Li, Cristina Pamfil, Simona Rednic, Tony R. Merriman, Tania O. Crișan, Leo A.B. Joosten
Gout is caused by the response of the innate immune system to monosodium urate (MSU) crystals. A recent gout GWAS identified a signal of genetic association at a locus encompassing IL1RN-IL1F10. Colocalisation analysis using Genotype Tissue Expression Database (GTEx) eQTL data showed that the signal overlaps with genetic control of IL1RN/IL1F10 gene expression. We assess the functional implications of IL1RN rs9973741, the lead gout-associated variant. We conducted functional validation of IL1RN rs9973741 in patients with gout and controls. The transcription level of IL1RN/IL1F10 was investigated in unstimulated or MSU-crystal co-stimulated PBMCs. Ex vivo functional assays were performed in PBMCs stimulated with C16 + MSU crystals or LPS for 24 h. Cytokine levels were assessed by ELISA. In unstimulated PBMCs, no association of IL1RN rs9973741 (gout risk allele G) to IL1RN expression was observed while IL-1F10 was hindered by low expression at both transcriptional and protein levels. However, G allele carriers showed lower IL1RN expression in PBMCs stimulated with C16/MSU crystal and lower concentrations of circulating IL-1Ra in both controls and gout patients. PBMCs depicted less spontaneous IL-1Ra release in GG homozygous controls and lower IL-1Ra production in response to C16 + MSU crystal costimulation in patients with gout. The G allele was associated with elevated IL-1β cytokine production in response to C16 + MSU crystal stimulation in controls. The gout risk allele G associates with lower circulating IL-1Ra, lower IL-1Ra production in PBMC assays and elevated IL-1β production in PBMCs challenged with C16 + MSU crystals but not in unchallenged cells. Our data indicate that the genetic signal that associates with gout at IL1RN-IL1F10 region functions to alter expression of IL-1Ra when stimulated by MSU crystals.
痛风是由先天性免疫系统对尿酸单钠(MSU)结晶的反应引起的。最近的一项痛风基因组学分析发现,在一个包含IL1RN-IL1F10的基因座上存在遗传关联信号。利用基因型组织表达数据库(GTEx)eQTL 数据进行的共定位分析表明,该信号与 IL1RN/IL1F10 基因表达的遗传控制重叠。我们评估了IL1RN rs9973741这一痛风相关变异的功能影响。我们在痛风患者和对照组中对 IL1RN rs9973741 进行了功能验证。在未刺激或 MSU 晶体共同刺激的 PBMCs 中调查了 IL1RN/IL1F10 的转录水平。细胞因子水平通过 ELISA 进行评估。在未受刺激的 PBMCs 中,未观察到 IL1RN rs9973741(痛风风险等位基因 G)与 IL1RN 表达的关系,而 IL-1F10 在转录和蛋白水平上的低表达则阻碍了 IL-1RN 的表达。然而,在对照组和痛风患者中,G 等位基因携带者在 C16/MSU 晶体刺激下的 PBMC 中 IL1RN 表达较低,循环 IL-1Ra 浓度也较低。在GG等位基因对照组中,PBMC自发释放的IL-1Ra较少,而在痛风患者中,IL-1Ra在C16+MSU晶体刺激下产生的较少。在对照组中,等位基因 G 与 C16 + MSU 晶体刺激下 IL-1β 细胞因子产生的升高有关。痛风风险等位基因 G 与较低的循环 IL-1Ra、PBMC 检测中较低的 IL-1Ra 生成以及受到 C16 + MSU 晶体刺激的 PBMC 中升高的 IL-1β 生成有关,但与未受到刺激的细胞无关。我们的数据表明,当受到 MSU 晶体刺激时,IL1RN-IL1F10 区域与痛风相关的遗传信号可改变 IL-1Ra 的表达。
{"title":"Gout-associated SNP at the IL1RN-IL1F10 region is associated with altered cytokine production in PBMCs of patients with gout and controls","authors":"Orsolya I. Gaal, Megan Leask, Valentin Nica, Georgiana Cabău, Medeea Badii, Ioana Hotea, Dennis M de Graaf, Zhenhua Zhang, Yang Li, Cristina Pamfil, Simona Rednic, Tony R. Merriman, Tania O. Crișan, Leo A.B. Joosten","doi":"10.1186/s13075-024-03436-0","DOIUrl":"https://doi.org/10.1186/s13075-024-03436-0","url":null,"abstract":"Gout is caused by the response of the innate immune system to monosodium urate (MSU) crystals. A recent gout GWAS identified a signal of genetic association at a locus encompassing IL1RN-IL1F10. Colocalisation analysis using Genotype Tissue Expression Database (GTEx) eQTL data showed that the signal overlaps with genetic control of IL1RN/IL1F10 gene expression. We assess the functional implications of IL1RN rs9973741, the lead gout-associated variant. We conducted functional validation of IL1RN rs9973741 in patients with gout and controls. The transcription level of IL1RN/IL1F10 was investigated in unstimulated or MSU-crystal co-stimulated PBMCs. Ex vivo functional assays were performed in PBMCs stimulated with C16 + MSU crystals or LPS for 24 h. Cytokine levels were assessed by ELISA. In unstimulated PBMCs, no association of IL1RN rs9973741 (gout risk allele G) to IL1RN expression was observed while IL-1F10 was hindered by low expression at both transcriptional and protein levels. However, G allele carriers showed lower IL1RN expression in PBMCs stimulated with C16/MSU crystal and lower concentrations of circulating IL-1Ra in both controls and gout patients. PBMCs depicted less spontaneous IL-1Ra release in GG homozygous controls and lower IL-1Ra production in response to C16 + MSU crystal costimulation in patients with gout. The G allele was associated with elevated IL-1β cytokine production in response to C16 + MSU crystal stimulation in controls. The gout risk allele G associates with lower circulating IL-1Ra, lower IL-1Ra production in PBMC assays and elevated IL-1β production in PBMCs challenged with C16 + MSU crystals but not in unchallenged cells. Our data indicate that the genetic signal that associates with gout at IL1RN-IL1F10 region functions to alter expression of IL-1Ra when stimulated by MSU crystals.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"170 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142673911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaphorin 5A promotes Th17 differentiation via PI3K-Akt-mTOR in systemic lupus erythematosus 半aphorin 5A 通过 PI3K-Akt-mTOR 促进系统性红斑狼疮中 Th17 的分化
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-19 DOI: 10.1186/s13075-024-03437-z
Xin Chen, Lingjiang Zhu, Jieying Xu, Qi Cheng, Yuanji Dong, Yifan Xie, Li Hua, Yan Du
Previously, we reported that serum Semaphorin 5 A (Sema5A) levels were increased in systemic lupus erythematosus (SLE) patients compared with healthy controls (HC), and elevated Sema5A correlated with disease activity and lupus nephritis in SLE patients. In this study, we aimed to further understand the role of Sema5A in promoting Th17 cells differentiation in SLE. Sema5A, interferon gamma (IFN-γ), interleukin 4 (IL-4), interleukin 17 A (IL-17 A) and interleukin 10 (IL-10) were measured by Enzyme Linked Immunosorbent Assay (ELISA). RNA and protein were isolated from peripheral blood mononuclear cells (PBMCs) in SLE patients and HC. Expression of PlexinA1 and PlexinB3 were measured by quantitative RT-PCR (qRT-PCR) and Western Blot. Th cell subsets were detected by flow cytometry. Treatment with recombinant human Sema5A (rhSema5A) and small interfering RNA (siRNA) were employed to examine the in vitro effect of Sema5A in CD4+T cell differentiation in SLE patients. IL-17 A elevated in SLE patients and positively correlated with Sema5A. PlexinA1 was upregulated and mainly expressed in CD4+ T cells of SLE; Sema5A treatment induced the differentiation of Th17 cells, while did not affect the Th1 and Th2 skewing. These effects were associated with an upregulation of the transcription factor RORγt by Th17 cells, but not T-bet or GATA3 in Th1 and Th2 cells, respectively. Knock down PlexinA1 regulates IL-17 A production by CD4+T cells. Functional assays showed that Sema5A-PlexinA1 axis promoted Th17 cells differentiation via PI3K/Akt/mTOR signaling. These findings demonstrated that Sema5A-PlexinA1 axis acts as a key mediator on Th17 differentiation, suggesting that Sema5A might be a novel therapeutic target in SLE.
此前,我们曾报道过系统性红斑狼疮(SLE)患者血清中的赛玛素5 A(Sema5A)水平与健康对照组(HC)相比有所增加,而且Sema5A的升高与系统性红斑狼疮患者的疾病活动性和狼疮性肾炎有关。本研究旨在进一步了解 Sema5A 在促进系统性红斑狼疮 Th17 细胞分化中的作用。研究采用酶联免疫吸附试验(ELISA)检测了Sema5A、γ干扰素(IFN-γ)、白细胞介素4(IL-4)、白细胞介素17 A(IL-17 A)和白细胞介素10(IL-10)。从系统性红斑狼疮患者和白血病患者的外周血单核细胞(PBMC)中分离出 RNA 和蛋白质。通过定量 RT-PCR (qRT-PCR) 和 Western Blot 检测 PlexinA1 和 PlexinB3 的表达。流式细胞术检测 Th 细胞亚群。用重组人 Sema5A(rhSema5A)和小干扰 RNA(siRNA)处理系统性红斑狼疮患者,以检测 Sema5A 在体外对 CD4+T 细胞分化的影响。系统性红斑狼疮患者的IL-17 A升高,并与Sema5A呈正相关。PlexinA1上调,主要在系统性红斑狼疮的CD4+T细胞中表达;Sema5A治疗诱导Th17细胞分化,而不影响Th1和Th2的倾斜。这些效应与Th17细胞转录因子RORγt的上调有关,但与Th1和Th2细胞中的T-bet或GATA3的上调无关。敲除 PlexinA1 可调节 CD4+T 细胞产生 IL-17 A。功能测定显示,Sema5A-PlexinA1轴通过PI3K/Akt/mTOR信号转导促进Th17细胞分化。这些研究结果表明,Sema5A-PlexinA1轴是Th17分化的一个关键介质,这表明Sema5A可能是系统性红斑狼疮的一个新的治疗靶点。
{"title":"Semaphorin 5A promotes Th17 differentiation via PI3K-Akt-mTOR in systemic lupus erythematosus","authors":"Xin Chen, Lingjiang Zhu, Jieying Xu, Qi Cheng, Yuanji Dong, Yifan Xie, Li Hua, Yan Du","doi":"10.1186/s13075-024-03437-z","DOIUrl":"https://doi.org/10.1186/s13075-024-03437-z","url":null,"abstract":"Previously, we reported that serum Semaphorin 5 A (Sema5A) levels were increased in systemic lupus erythematosus (SLE) patients compared with healthy controls (HC), and elevated Sema5A correlated with disease activity and lupus nephritis in SLE patients. In this study, we aimed to further understand the role of Sema5A in promoting Th17 cells differentiation in SLE. Sema5A, interferon gamma (IFN-γ), interleukin 4 (IL-4), interleukin 17 A (IL-17 A) and interleukin 10 (IL-10) were measured by Enzyme Linked Immunosorbent Assay (ELISA). RNA and protein were isolated from peripheral blood mononuclear cells (PBMCs) in SLE patients and HC. Expression of PlexinA1 and PlexinB3 were measured by quantitative RT-PCR (qRT-PCR) and Western Blot. Th cell subsets were detected by flow cytometry. Treatment with recombinant human Sema5A (rhSema5A) and small interfering RNA (siRNA) were employed to examine the in vitro effect of Sema5A in CD4+T cell differentiation in SLE patients. IL-17 A elevated in SLE patients and positively correlated with Sema5A. PlexinA1 was upregulated and mainly expressed in CD4+ T cells of SLE; Sema5A treatment induced the differentiation of Th17 cells, while did not affect the Th1 and Th2 skewing. These effects were associated with an upregulation of the transcription factor RORγt by Th17 cells, but not T-bet or GATA3 in Th1 and Th2 cells, respectively. Knock down PlexinA1 regulates IL-17 A production by CD4+T cells. Functional assays showed that Sema5A-PlexinA1 axis promoted Th17 cells differentiation via PI3K/Akt/mTOR signaling. These findings demonstrated that Sema5A-PlexinA1 axis acts as a key mediator on Th17 differentiation, suggesting that Sema5A might be a novel therapeutic target in SLE.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"6 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142670815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus. 间充质干细胞提取的细胞外囊泡与疾病条件免疫细胞对系统性红斑狼疮的治疗效果。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-18 DOI: 10.1186/s13075-024-03435-1
Eun Wha Choi, Il Seob Shin, I-Rang Lim, Jihye Lee, Bongkum Choi, Sungjoo Kim

Background: Systemic lupus erythematosus (SLE) is an incurable chronic autoimmune disease of unknown etiology. Therefore, the development of new treatments is urgently needed. This study aimed to investigate the therapeutic effects of extracellular vesicles (EV) derived from immortalized mesenchymal stem cells (iMSCs) primed with conditioned media obtained from disease-conditioned immune cells (CM-EV) and iMSC-derived EV (ASC-EV) in a murine model of SLE.

Methods: Female NZB/W F1 mice were divided into the control (C, n = 15), ASC-EV (E, n = 15), and CM-EV (CM, n = 15) groups. Mice in the C, E, and CM groups were intravenously administered saline, ASC-EV, and CM-EV, respectively, once weekly from 6 to 42 weeks of age.

Results: Compared to the ASC-EV, the CM-EV showed a significant increase in TGF-β1 production and miR-155-5p and miR-142-3p expression. CM-EV treatment increased survival, decreased anti-dsDNA antibody levels, and ameliorated renal histopathology. Although ASC-EV treatment significantly reduced the incidence of severe proteinuria and improved renal histopathology, it did not significantly improve survival rate. ASC-EV or CM-EV treatment significantly decreased the proportion of pro-inflammatory macrophages (CD11c + CD206-; M1) and M1:M2 ratio. Additionally, CM-EV treatment significantly increased the expression of anti-inflammatory macrophages (CD11c-CD206 + ; M2). Moreover, CM-EV treatment significantly decreased the expression of lupus-specific miRNAs (miR-182-5p and miR-183-5p) in the spleen.

Conclusions: EV derived from iMSCs primed with conditioned media obtained from disease-conditioned immune cells exert immunomodulatory effects and ameliorate SLE in a murine model.

背景:系统性红斑狼疮(SLE)是一种病因不明、无法治愈的慢性自身免疫性疾病。因此,迫切需要开发新的治疗方法。本研究的目的是探讨用从疾病条件免疫细胞(CM-EV)和iMSC衍生EV(ASC-EV)获得的条件培养基诱导的永生化间充质干细胞(iMSC)衍生的胞外囊泡(EV)在小鼠系统性红斑狼疮模型中的治疗效果:将雌性 NZB/W F1 小鼠分为对照组(C,n = 15)、ASC-EV 组(E,n = 15)和 CM-EV 组(CM,n = 15)。C组、E组和CM组的小鼠在6至42周龄期间每周分别静脉注射一次生理盐水、ASC-EV和CM-EV:结果:与ASC-EV相比,CM-EV显著增加了TGF-β1的产生以及miR-155-5p和miR-142-3p的表达。CM-EV治疗提高了存活率,降低了抗dsDNA抗体水平,并改善了肾组织病理学。虽然ASC-EV治疗能显著降低严重蛋白尿的发生率并改善肾组织病理学,但并不能显著提高存活率。ASC-EV或CM-EV治疗可明显降低促炎性巨噬细胞(CD11c + CD206-; M1)的比例和M1:M2比例。此外,CM-EV 治疗能明显增加抗炎巨噬细胞(CD11c-CD206 + ;M2)的表达。此外,CM-EV还能明显降低脾脏中狼疮特异性miRNA(miR-182-5p和miR-183-5p)的表达:结论:由iMSCs提取的EV在小鼠模型中利用从疾病条件免疫细胞中获得的条件培养基发挥免疫调节作用并改善系统性红斑狼疮。
{"title":"Therapeutic effects of extracellular vesicles derived from mesenchymal stem cells primed with disease-conditioned-immune cells in systemic lupus erythematosus.","authors":"Eun Wha Choi, Il Seob Shin, I-Rang Lim, Jihye Lee, Bongkum Choi, Sungjoo Kim","doi":"10.1186/s13075-024-03435-1","DOIUrl":"10.1186/s13075-024-03435-1","url":null,"abstract":"<p><strong>Background: </strong>Systemic lupus erythematosus (SLE) is an incurable chronic autoimmune disease of unknown etiology. Therefore, the development of new treatments is urgently needed. This study aimed to investigate the therapeutic effects of extracellular vesicles (EV) derived from immortalized mesenchymal stem cells (iMSCs) primed with conditioned media obtained from disease-conditioned immune cells (CM-EV) and iMSC-derived EV (ASC-EV) in a murine model of SLE.</p><p><strong>Methods: </strong>Female NZB/W F1 mice were divided into the control (C, n = 15), ASC-EV (E, n = 15), and CM-EV (CM, n = 15) groups. Mice in the C, E, and CM groups were intravenously administered saline, ASC-EV, and CM-EV, respectively, once weekly from 6 to 42 weeks of age.</p><p><strong>Results: </strong>Compared to the ASC-EV, the CM-EV showed a significant increase in TGF-β1 production and miR-155-5p and miR-142-3p expression. CM-EV treatment increased survival, decreased anti-dsDNA antibody levels, and ameliorated renal histopathology. Although ASC-EV treatment significantly reduced the incidence of severe proteinuria and improved renal histopathology, it did not significantly improve survival rate. ASC-EV or CM-EV treatment significantly decreased the proportion of pro-inflammatory macrophages (CD11c + CD206-; M1) and M1:M2 ratio. Additionally, CM-EV treatment significantly increased the expression of anti-inflammatory macrophages (CD11c-CD206 + ; M2). Moreover, CM-EV treatment significantly decreased the expression of lupus-specific miRNAs (miR-182-5p and miR-183-5p) in the spleen.</p><p><strong>Conclusions: </strong>EV derived from iMSCs primed with conditioned media obtained from disease-conditioned immune cells exert immunomodulatory effects and ameliorate SLE in a murine model.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"26 1","pages":"201"},"PeriodicalIF":4.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automatic knee osteoarthritis severity grading based on X-ray images using a hierarchical classification method. 基于X光图像的膝关节骨关节炎严重程度自动分级分层分类法。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-18 DOI: 10.1186/s13075-024-03416-4
Jian Pan, Yuangang Wu, Zhenchao Tang, Kaibo Sun, Mingyang Li, Jiayu Sun, Jiangang Liu, Jie Tian, Bin Shen

Background: This study aims to develop a hierarchical classification method to automatically assess the severity of knee osteoarthritis (KOA).

Methods: This retrospective study recruited 4074 patients. Clinical diagnostic indicators and clinical diagnostic processes were applied to develop a hierarchical classification method that involved four sub-task classifications. These four sub-task classifications were the classification of Kellgren-Lawrence (KL) grade 0-2 and KL grade 3-4, KL grade 3 and KL grade 4, KL grade 0 and KL grade 1-2, and KL grade 1 and KL grade 2, respectively. To extract the features of clinical diagnostic indicators, four U-Net models were first used to segment the total joint space (TJS), the lateral joint space (LJS), the medial joint space (MJS), and osteophytes, respectively. Based on the segmentation result of TJS, the region of knee subchondral bone was generated. Then, geometric features were extracted based on segmentation results of the LJS, MJS, TJS, and osteophytes, while radiomic features were extracted from the knee subchondral bone. Finally, the geometric features, radiomic features, and combination of geometric features and radiomic features were used to construct the geometric model, radiomic model, and combined model in KL grading, respectively. A strict decision strategy was used to evaluate the performance of the hierarchical classification method in all X-ray images of testing cohort.

Results: The U-Net models achieved relatively satisfying performances in the segmentation of the TJS, the LJS, the MJS, and the osteophytes with the dice similarity coefficient of 0.88, 0.86, 0.88, and 0.64 respectively. The combined models achieved the best performance in KL grading. The accuracy of combined models was 98.50%, 81.65%, 82.07%, and 74.10% in the classification of KL grade 0-2 and KL grade 3-4, KL grade 3 and KL grade 4, KL grade 0 and KL grade 1-2, and KL grade 1 and KL grade 2, respectively. For all X-ray images of the testing cohort, the accuracy of the hierarchical classification method was 65.98%.

Conclusion: The hierarchical classification method developed in the current study is a feasible approach to assess the severity of KOA.

背景:本研究旨在开发一种分层分类方法,用于自动评估膝骨关节炎(KOA)的严重程度:本研究旨在开发一种分层分类方法,用于自动评估膝关节骨性关节炎(KOA)的严重程度:这项回顾性研究共招募了 4074 名患者。应用临床诊断指标和临床诊断流程开发了一种分级分类方法,其中包括四个子任务分类。这四个子任务分类分别为 Kellgren-Lawrence(KL)0-2 级和 KL 3-4 级、KL 3 级和 KL 4 级、KL 0 级和 KL 1-2 级、KL 1 级和 KL 2 级。为了提取临床诊断指标的特征,首先使用四个 U-Net 模型分别对全关节间隙(TJS)、外侧关节间隙(LJS)、内侧关节间隙(MJS)和骨质增生进行分割。根据 TJS 的分割结果,生成膝关节软骨下骨区域。然后,根据内侧关节间隙(LJS)、外侧关节间隙(MJS)、内侧关节间隙(TJS)和骨质增生的分割结果提取几何特征,并从膝关节软骨下骨提取放射学特征。最后,在 KL 分级中分别使用几何特征、放射学特征以及几何特征和放射学特征的组合构建几何模型、放射学模型和组合模型。采用严格的决策策略来评估分层分类方法在测试组群所有 X 光图像中的性能:结果:U-Net模型在TJS、LJS、MJS和骨质增生的分割中取得了相对令人满意的表现,骰子相似系数分别为0.88、0.86、0.88和0.64。组合模型在 KL 分级中表现最佳。在 KL 0-2 级和 KL 3-4 级、KL 3 级和 KL 4 级、KL 0 级和 KL 1-2 级、KL 1 级和 KL 2 级的分类中,组合模型的准确率分别为 98.50%、81.65%、82.07% 和 74.10%。对于测试组群的所有 X 光图像,分级分类法的准确率为 65.98%:结论:本研究开发的分级分类法是评估 KOA 严重程度的可行方法。
{"title":"Automatic knee osteoarthritis severity grading based on X-ray images using a hierarchical classification method.","authors":"Jian Pan, Yuangang Wu, Zhenchao Tang, Kaibo Sun, Mingyang Li, Jiayu Sun, Jiangang Liu, Jie Tian, Bin Shen","doi":"10.1186/s13075-024-03416-4","DOIUrl":"10.1186/s13075-024-03416-4","url":null,"abstract":"<p><strong>Background: </strong>This study aims to develop a hierarchical classification method to automatically assess the severity of knee osteoarthritis (KOA).</p><p><strong>Methods: </strong>This retrospective study recruited 4074 patients. Clinical diagnostic indicators and clinical diagnostic processes were applied to develop a hierarchical classification method that involved four sub-task classifications. These four sub-task classifications were the classification of Kellgren-Lawrence (KL) grade 0-2 and KL grade 3-4, KL grade 3 and KL grade 4, KL grade 0 and KL grade 1-2, and KL grade 1 and KL grade 2, respectively. To extract the features of clinical diagnostic indicators, four U-Net models were first used to segment the total joint space (TJS), the lateral joint space (LJS), the medial joint space (MJS), and osteophytes, respectively. Based on the segmentation result of TJS, the region of knee subchondral bone was generated. Then, geometric features were extracted based on segmentation results of the LJS, MJS, TJS, and osteophytes, while radiomic features were extracted from the knee subchondral bone. Finally, the geometric features, radiomic features, and combination of geometric features and radiomic features were used to construct the geometric model, radiomic model, and combined model in KL grading, respectively. A strict decision strategy was used to evaluate the performance of the hierarchical classification method in all X-ray images of testing cohort.</p><p><strong>Results: </strong>The U-Net models achieved relatively satisfying performances in the segmentation of the TJS, the LJS, the MJS, and the osteophytes with the dice similarity coefficient of 0.88, 0.86, 0.88, and 0.64 respectively. The combined models achieved the best performance in KL grading. The accuracy of combined models was 98.50%, 81.65%, 82.07%, and 74.10% in the classification of KL grade 0-2 and KL grade 3-4, KL grade 3 and KL grade 4, KL grade 0 and KL grade 1-2, and KL grade 1 and KL grade 2, respectively. For all X-ray images of the testing cohort, the accuracy of the hierarchical classification method was 65.98%.</p><p><strong>Conclusion: </strong>The hierarchical classification method developed in the current study is a feasible approach to assess the severity of KOA.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"26 1","pages":"203"},"PeriodicalIF":4.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571664/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correlation between circulating cell-free mitochondrial DNA content and severity of knee degeneration in patients with knee osteoarthritis: a cross-sectional study. 循环细胞游离线粒体 DNA 含量与膝关节骨关节炎患者膝关节退化严重程度的相关性:一项横断面研究。
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-18 DOI: 10.1186/s13075-024-03438-y
Yan-Lin Wu, Shao-Gui Wan, Yi Long, Hua Ye, Jia-Ming Yang, Yun Luo, Yan-Biao Zhong, Li Xiao, Hai-Yan Chen, Mao-Yuan Wang

Background: Knee osteoarthritis (KOA) is characterized by mitochondrial damage and increased inflammation. Circulating cell-free mitochondrial DNA (ccf-mtDNA), which originates from damaged mitochondria, is an endogenous damage-associated molecular pattern (DAMPs) molecule that may trigger inflammation and is recognized as a potential biomarker for various diseases. In this study, we investigated the potential association between plasma ccf-mtDNA content and its use as a diagnostic biomarker in patients with KOA.

Methods: We collected plasma samples from patients with KOA and healthy controls (HC). Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect ccf-mtDNA content in the plasma samples. We used the Kellgren-Lawrence (K-L) classification criteria to classify patients with KOA into four grades: I-IV. Disease severity in patients with KOA was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Next, Spearman analysis was performed to observe the correlation between ccf-mtDNA content and the K-L classification and WOMAC score. Logistic regression analysis was used to evaluate the relationship between ccf-mtDNA and KOA risk.

Results: In total, we enrolled 60 patients with KOA and HC who were matched for age, sex, and body mass index (BMI). We found that plasma ccf-mtDNA contents were significantly higher in patients with KOA (median, 2.44; quartile range, 1.10-3.79) than in HC (median, 1.08; quartile range, 0.52-2.12) (P < 0.0001). Plasma ccf-mtDNA content sequentially increased following the KOA class I-IV group (P = 0.040) and positively correlated with the K-L classification (r = 0.369, P = 0.004) and WOMAC scores (r = 0.343, P = 0.007). The ccf-mtDNA content did not significantly differ between patients with bilateral and those with single KOA (P = 0.083). Patients with high levels of ccf-mtDNA had a significantly increased risk of KOA compared with those with low levels of ccf-mtDNA (odds ratio [OR], 4.15, 95% confidence interval [CI], 1.71-10.07; P = 0.002). Quartile analysis revealed a significant dose-dependent association (P trend < 0.001).

Conclusion: Our study's findings showed that plasma ccf-mtDNA was highly expressed in patients with KOA compared with HC. Furthermore, ccf-mtDNA content is significantly associated with the severity and risk of KOA. Therefore, its detection may provide insight into the prevention and treatment of KOA.

背景:膝骨关节炎(KOA)的特点是线粒体损伤和炎症加剧。循环游离细胞线粒体 DNA(ccf-mtDNA)来源于受损的线粒体,是一种内源性损伤相关分子模式(DAMPs)分子,可能引发炎症,被认为是各种疾病的潜在生物标志物。在这项研究中,我们探讨了血浆中ccf-mtDNA含量与将其作为KOA患者诊断生物标志物之间的潜在关联:方法:我们采集了 KOA 患者和健康对照组(HC)的血浆样本。方法:我们采集了 KOA 患者和健康对照组(HC)的血浆样本,然后使用定量实时聚合酶链反应(qRT-PCR)检测血浆样本中的 ccf-mtDNA 含量。我们采用凯尔格伦-劳伦斯(Kellgren-Lawrence,K-L)分级标准将 KOA 患者分为四级:I-IV。我们使用西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评估了KOA患者的疾病严重程度。接着,进行了斯皮尔曼分析,以观察ccf-mtDNA含量与K-L分类和WOMAC评分之间的相关性。逻辑回归分析用于评估ccf-mtDNA与KOA风险之间的关系:我们共招募了 60 名 KOA 和 HC 患者,他们的年龄、性别和体重指数(BMI)均匹配。我们发现,KOA 患者的血浆 ccf-mtDNA 含量(中位数,2.44;四分位数范围,1.10-3.79)明显高于 HC 患者(中位数,1.08;四分位数范围,0.52-2.12)(P 结论:我们的研究结果表明,KOA 患者的血浆 ccf-mtDNA 含量明显高于 HC 患者:我们的研究结果表明,与 HC 相比,KOA 患者的血浆 ccf-mtDNA 表达量较高。此外,ccf-mtDNA 含量与 KOA 的严重程度和风险显著相关。因此,检测ccf-mtDNA可能有助于KOA的预防和治疗。
{"title":"Correlation between circulating cell-free mitochondrial DNA content and severity of knee degeneration in patients with knee osteoarthritis: a cross-sectional study.","authors":"Yan-Lin Wu, Shao-Gui Wan, Yi Long, Hua Ye, Jia-Ming Yang, Yun Luo, Yan-Biao Zhong, Li Xiao, Hai-Yan Chen, Mao-Yuan Wang","doi":"10.1186/s13075-024-03438-y","DOIUrl":"10.1186/s13075-024-03438-y","url":null,"abstract":"<p><strong>Background: </strong>Knee osteoarthritis (KOA) is characterized by mitochondrial damage and increased inflammation. Circulating cell-free mitochondrial DNA (ccf-mtDNA), which originates from damaged mitochondria, is an endogenous damage-associated molecular pattern (DAMPs) molecule that may trigger inflammation and is recognized as a potential biomarker for various diseases. In this study, we investigated the potential association between plasma ccf-mtDNA content and its use as a diagnostic biomarker in patients with KOA.</p><p><strong>Methods: </strong>We collected plasma samples from patients with KOA and healthy controls (HC). Subsequently, quantitative real-time polymerase chain reaction (qRT-PCR) was used to detect ccf-mtDNA content in the plasma samples. We used the Kellgren-Lawrence (K-L) classification criteria to classify patients with KOA into four grades: I-IV. Disease severity in patients with KOA was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Next, Spearman analysis was performed to observe the correlation between ccf-mtDNA content and the K-L classification and WOMAC score. Logistic regression analysis was used to evaluate the relationship between ccf-mtDNA and KOA risk.</p><p><strong>Results: </strong>In total, we enrolled 60 patients with KOA and HC who were matched for age, sex, and body mass index (BMI). We found that plasma ccf-mtDNA contents were significantly higher in patients with KOA (median, 2.44; quartile range, 1.10-3.79) than in HC (median, 1.08; quartile range, 0.52-2.12) (P < 0.0001). Plasma ccf-mtDNA content sequentially increased following the KOA class I-IV group (P = 0.040) and positively correlated with the K-L classification (r = 0.369, P = 0.004) and WOMAC scores (r = 0.343, P = 0.007). The ccf-mtDNA content did not significantly differ between patients with bilateral and those with single KOA (P = 0.083). Patients with high levels of ccf-mtDNA had a significantly increased risk of KOA compared with those with low levels of ccf-mtDNA (odds ratio [OR], 4.15, 95% confidence interval [CI], 1.71-10.07; P = 0.002). Quartile analysis revealed a significant dose-dependent association (P trend < 0.001).</p><p><strong>Conclusion: </strong>Our study's findings showed that plasma ccf-mtDNA was highly expressed in patients with KOA compared with HC. Furthermore, ccf-mtDNA content is significantly associated with the severity and risk of KOA. Therefore, its detection may provide insight into the prevention and treatment of KOA.</p>","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"26 1","pages":"202"},"PeriodicalIF":4.9,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11571657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142666840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study 达达替尼对生物制剂疗法难治的活动性强直性脊柱炎患者的疗效和安全性:SELECT-AXIS 2研究开放标签延长期的两年临床和影像学结果
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-12 DOI: 10.1186/s13075-024-03412-8
Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar
The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study. Here, we assess 2-year efficacy, safety, and imaging outcomes in SELECT-AXIS 2. Patients who received continuous upadacitinib, and those who switched from placebo to upadacitinib at week 14, could enter the open-label extension (OLE). Efficacy endpoints included Assessment of SpondyloArthritis international Society (ASAS) and Axial Spondyloarthritis Disease Activity Score (ASDAS) responses, and changes from baseline in measures of disease activity, back pain, function, and quality of life. Radiographic progression was evaluated using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). As observed (AO) and AO with non-responder imputation (AO-NRI) analyses were used for binary endpoints; AO with mixed-effects model for repeated measures (AO-MMRM) for continuous endpoints; and AO-analysis of covariance for mSASSS. Treatment-emergent adverse events (TEAEs) in patients receiving ≥ 1 upadacitinib dose through week 104 are presented as events (E)/100 patient-years (PY). Subgroup analyses were performed by prior tumor necrosis factor/interleukin-17 inhibitor exposure and bDMARD lack of efficacy/intolerance. Of 420 patients who entered the bDMARD-IR AS study, 409 entered the OLE, and 331 (continuous upadacitinib, n = 163; placebo to upadacitinib, n = 168) completed week 104. Improvements in efficacy measures were sustained through the OLE, with similar response rates between the continuous upadacitinib and placebo to upadacitinib groups at week 104. At week 104, 64.9% and 61.7% of patients, respectively, had achieved ASAS 40% response (AO-NRI). Mean changes from baseline were similar between the two groups at week 104 across measures (ASDAS: -2.1 and -2.0; total back pain: -4.9 and -4.6, respectively; AO-MMRM). Over 93.0% of patients showed no radiographic progression (mSASSS mean change from baseline < 2) at week 104. The overall TEAE rate was 165.2 E/100 PY, with low rates of major adverse cardiovascular and venous thromboembolic events (0.3 E/100 PY each). Upadacitinib efficacy, including very low rates of radiographic progression, was demonstrated through 104 weeks in treatment-refractory patients with active AS. Treatment was well tolerated, with no newly identified safety signals. NCT04169373.
SELECT-AXIS 2研究评估了达达替尼治疗强直性脊柱炎(AS)和对生物改善病情抗风湿药(bDMARD-IR)反应不佳/不耐受患者一年的疗效和安全性。在此,我们将评估 SELECT-AXIS 2 的 2 年疗效、安全性和影像学结果。连续接受达达替尼治疗的患者以及在第 14 周从安慰剂转为达达替尼治疗的患者可进入开放标签扩展期(OLE)。疗效终点包括脊柱关节炎国际协会(ASAS)和轴性脊柱关节炎疾病活动度评分(ASDAS)反应评估,以及疾病活动度、背痛、功能和生活质量与基线相比的变化。使用改良的斯托克强直性脊柱炎脊柱评分(mSASSS)评估放射学进展。二元终点采用观察分析(AO)和AO与非应答者归因分析(AO-NRI);连续终点采用AO与重复测量混合效应模型(AO-MMRM);mSASSS采用AO-协方差分析。在第104周之前接受≥1次达帕替尼治疗的患者发生的治疗突发不良事件(TEAEs)以事件(E)/100患者年(PY)表示。根据既往肿瘤坏死因子/白细胞介素-17抑制剂暴露情况和 bDMARD 缺乏疗效/不耐受情况进行了亚组分析。在420名参加bDMARD-IR AS研究的患者中,409名参加了OLE,331名(连续服用达帕替尼者,n=163;安慰剂改为达帕替尼者,n=168)完成了第104周的治疗。在OLE期间,疗效指标的改善得以持续,在第104周时,连续服用奥达帕替尼组和安慰剂对奥达帕替尼组的应答率相似。第104周时,分别有64.9%和61.7%的患者达到了ASAS 40%的应答率(AO-NRI)。第104周时,两组患者在各项指标上与基线相比的平均变化相似(ASDAS:-2.1和-2.0;总背痛:-4.9和-4.6;AO-MMRM)。超过 93.0% 的患者在第 104 周时没有出现放射学进展(mSASSS 与基线相比的平均变化 < 2)。总体TEAE率为165.2 E/100PY,主要不良心血管事件和静脉血栓栓塞事件发生率较低(各为0.3 E/100PY)。在治疗难治的活动性强直性脊柱炎患者中,乌达替尼的疗效(包括极低的放射学进展发生率)已在104周的治疗中得到证实。治疗耐受性良好,没有发现新的安全信号。NCT04169373。
{"title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study","authors":"Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar","doi":"10.1186/s13075-024-03412-8","DOIUrl":"https://doi.org/10.1186/s13075-024-03412-8","url":null,"abstract":"The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study. Here, we assess 2-year efficacy, safety, and imaging outcomes in SELECT-AXIS 2. Patients who received continuous upadacitinib, and those who switched from placebo to upadacitinib at week 14, could enter the open-label extension (OLE). Efficacy endpoints included Assessment of SpondyloArthritis international Society (ASAS) and Axial Spondyloarthritis Disease Activity Score (ASDAS) responses, and changes from baseline in measures of disease activity, back pain, function, and quality of life. Radiographic progression was evaluated using the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). As observed (AO) and AO with non-responder imputation (AO-NRI) analyses were used for binary endpoints; AO with mixed-effects model for repeated measures (AO-MMRM) for continuous endpoints; and AO-analysis of covariance for mSASSS. Treatment-emergent adverse events (TEAEs) in patients receiving ≥ 1 upadacitinib dose through week 104 are presented as events (E)/100 patient-years (PY). Subgroup analyses were performed by prior tumor necrosis factor/interleukin-17 inhibitor exposure and bDMARD lack of efficacy/intolerance. Of 420 patients who entered the bDMARD-IR AS study, 409 entered the OLE, and 331 (continuous upadacitinib, n = 163; placebo to upadacitinib, n = 168) completed week 104. Improvements in efficacy measures were sustained through the OLE, with similar response rates between the continuous upadacitinib and placebo to upadacitinib groups at week 104. At week 104, 64.9% and 61.7% of patients, respectively, had achieved ASAS 40% response (AO-NRI). Mean changes from baseline were similar between the two groups at week 104 across measures (ASDAS: -2.1 and -2.0; total back pain: -4.9 and -4.6, respectively; AO-MMRM). Over 93.0% of patients showed no radiographic progression (mSASSS mean change from baseline < 2) at week 104. The overall TEAE rate was 165.2 E/100 PY, with low rates of major adverse cardiovascular and venous thromboembolic events (0.3 E/100 PY each). Upadacitinib efficacy, including very low rates of radiographic progression, was demonstrated through 104 weeks in treatment-refractory patients with active AS. Treatment was well tolerated, with no newly identified safety signals. NCT04169373.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"95 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small heterodimer partner-interacting leucine zipper protein suppresses pain and cartilage destruction in an osteoarthritis model by modulating the AMPK/STAT3 signaling pathway 通过调节 AMPK/STAT3 信号通路抑制骨关节炎模型中的疼痛和软骨损伤
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-12 DOI: 10.1186/s13075-024-03417-3
Jeonghyeon Moon, Keun-Hyung Cho, JooYeon Jhun, JeongWon Choi, Hyun-Sik Na, Jeong Su Lee, Seung Yoon Lee, Jun-Ki Min, Anan Shetty, Sung-Hwan Park, Seok Jung Kim, Mi-La Cho
Osteoarthritis (OA) is a degenerative joint disease caused by the breakdown of joint cartilage and adjacent bone. Joint injury, being overweight, differences in leg length, high levels of joint stress, abnormal joint or limb development, and inherited factors have been implicated in the etiology of OA. In addition to physical damage to the joint, a role for inflammatory processes has been identified as well. Small heterodimer partner-interacting leucine zipper protein (SMILE) regulates transcription and many cellular functions. Among the proteins activated by SMILE is the peroxisome proliferator-activated receptor (PPAR) γ, which mediates the activities of CD4 + T helper cells, including Th1, Th2, and Th17, as well as Treg cells. PPAR-γ binds to STAT3 to inhibit its transcription, thereby suppressing the expression of the NF-κB pathway, and in turn, the expression of the inflammatory cytokines interferon (IFN), interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, which are sub-signals of STAT3 and NF-κB. OA was induced in control C57BL/6 mice and in C57BL/6-derived SMILE-overexpressing transgenic (SMILE Tg) mice. The protein expression levels in the joint and spleen tissues were analyzed by immunohistochemistry and immunofluorescence images. In addition, flow cytometry was performed for detecting changes of the changes of immune cells. Less cartilage damage and significantly reduced levels of OA biomarkers (MMP13, TIMP3 and MCP-1) were observed in SMILE Tg mice. Immunohistochemistry performed to identify the signaling pathway involved in the link between SMILE expression and OA revealed decreased levels of IL-1β, IL-6, TNF-α, and phosphorylated AMPK in synovial tissues as well as a significant decrease in phosphorylated STAT3 in both cartilage and synovium. Changes in systemic immune cells were investigated via flow cytometry to analyze splenocytes isolated from control and SMILE Tg mice. SMILE Tg mice had elevated proportions of CD4 + IL-4 + cells (Th2) and CD4 + CD25 + Foxp3 + cells (Treg) and a notable decrease in CD4 + IL-17 + cells (Th17). Our results show that overexpressed SMILE attenuates the symptoms of OA, by increasing AMPK signaling and decreasing STAT3, thus reducing the levels of inflammatory immune cells.
骨关节炎(OA)是一种退行性关节疾病,由关节软骨和邻近骨质破坏引起。关节损伤、超重、腿长短不一、关节压力过大、关节或肢体发育异常以及遗传因素都与 OA 的病因有关。除了关节的物理损伤外,炎症过程的作用也已被确认。小异质二聚体相互作用亮氨酸拉链蛋白(SMILE)调节转录和许多细胞功能。SMILE 激活的蛋白质包括过氧化物酶体增殖激活受体(PPAR)γ,它介导 CD4 + T 辅助细胞(包括 Th1、Th2 和 Th17)以及 Treg 细胞的活动。PPAR-γ 与 STAT3 结合以抑制其转录,从而抑制 NF-κB 通路的表达,进而抑制炎症细胞因子干扰素 (IFN)、白细胞介素 (IL)-1β、IL-6 和肿瘤坏死因子 (TNF)-α 的表达,它们是 STAT3 和 NF-κB 的子信号。在对照组C57BL/6小鼠和C57BL/6衍生的SMILE高表达转基因(SMILE Tg)小鼠中诱导OA。通过免疫组化和免疫荧光图像分析了关节和脾脏组织中的蛋白表达水平。此外,还采用流式细胞术检测免疫细胞的变化。在SMILE Tg小鼠中观察到的软骨损伤较少,OA生物标志物(MMP13、TIMP3和MCP-1)水平明显降低。为确定SMILE表达与OA之间的联系所涉及的信号通路而进行的免疫组化显示,滑膜组织中的IL-1β、IL-6、TNF-α和磷酸化AMPK水平下降,软骨和滑膜中的磷酸化STAT3水平也显著下降。通过流式细胞术分析从对照组和 SMILE Tg 小鼠体内分离出来的脾细胞,研究了全身免疫细胞的变化。SMILE Tg 小鼠的 CD4 + IL-4 + 细胞(Th2)和 CD4 + CD25 + Foxp3 + 细胞(Treg)比例升高,而 CD4 + IL-17 + 细胞(Th17)明显减少。我们的研究结果表明,过表达的SMILE通过增加AMPK信号传导和减少STAT3,从而降低炎性免疫细胞的水平,减轻了OA的症状。
{"title":"Small heterodimer partner-interacting leucine zipper protein suppresses pain and cartilage destruction in an osteoarthritis model by modulating the AMPK/STAT3 signaling pathway","authors":"Jeonghyeon Moon, Keun-Hyung Cho, JooYeon Jhun, JeongWon Choi, Hyun-Sik Na, Jeong Su Lee, Seung Yoon Lee, Jun-Ki Min, Anan Shetty, Sung-Hwan Park, Seok Jung Kim, Mi-La Cho","doi":"10.1186/s13075-024-03417-3","DOIUrl":"https://doi.org/10.1186/s13075-024-03417-3","url":null,"abstract":"Osteoarthritis (OA) is a degenerative joint disease caused by the breakdown of joint cartilage and adjacent bone. Joint injury, being overweight, differences in leg length, high levels of joint stress, abnormal joint or limb development, and inherited factors have been implicated in the etiology of OA. In addition to physical damage to the joint, a role for inflammatory processes has been identified as well. Small heterodimer partner-interacting leucine zipper protein (SMILE) regulates transcription and many cellular functions. Among the proteins activated by SMILE is the peroxisome proliferator-activated receptor (PPAR) γ, which mediates the activities of CD4 + T helper cells, including Th1, Th2, and Th17, as well as Treg cells. PPAR-γ binds to STAT3 to inhibit its transcription, thereby suppressing the expression of the NF-κB pathway, and in turn, the expression of the inflammatory cytokines interferon (IFN), interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α, which are sub-signals of STAT3 and NF-κB. OA was induced in control C57BL/6 mice and in C57BL/6-derived SMILE-overexpressing transgenic (SMILE Tg) mice. The protein expression levels in the joint and spleen tissues were analyzed by immunohistochemistry and immunofluorescence images. In addition, flow cytometry was performed for detecting changes of the changes of immune cells. Less cartilage damage and significantly reduced levels of OA biomarkers (MMP13, TIMP3 and MCP-1) were observed in SMILE Tg mice. Immunohistochemistry performed to identify the signaling pathway involved in the link between SMILE expression and OA revealed decreased levels of IL-1β, IL-6, TNF-α, and phosphorylated AMPK in synovial tissues as well as a significant decrease in phosphorylated STAT3 in both cartilage and synovium. Changes in systemic immune cells were investigated via flow cytometry to analyze splenocytes isolated from control and SMILE Tg mice. SMILE Tg mice had elevated proportions of CD4 + IL-4 + cells (Th2) and CD4 + CD25 + Foxp3 + cells (Treg) and a notable decrease in CD4 + IL-17 + cells (Th17). Our results show that overexpressed SMILE attenuates the symptoms of OA, by increasing AMPK signaling and decreasing STAT3, thus reducing the levels of inflammatory immune cells.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"36 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA) 系统性红斑狼疮患者预防肺孢子虫肺炎的临床实践模式:一项来自全国性机构狼疮登记处(LUNA)的横断面研究
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-12 DOI: 10.1186/s13075-024-03434-2
Takahisa Onishi, Ken-ei Sada, Keigo Hayashi, Yoshia Miyawaki, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Nobuyuki Yajima, Takashi Kida, Yusuke Matsuo, Keisuke Nishimura, Takashi Yamane
Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in patients undergoing immunosuppressive therapy, such as glucocorticoid (GC) medication, for systemic autoimmune diseases like systemic lupus erythematosus (SLE). Despite the confirmed effectiveness of PCP prophylaxis, its clinical administration, especially in conjunction with GC dosage, remains unclear. We aimed to describe the clinical practice of PCP prophylaxis in association with SLE in Japan, evaluate the relationship between GC dosage and PCP prophylaxis, and explore the practice patterns associated with PCP prophylaxis. This cross-sectional study used data from the Lupus Registry of Nationwide Institutions in Japan from 2016 to 2021 and included patients diagnosed with SLE. Using descriptive statistics, multivariate analysis, and decision tree analysis, we examined the prevalence of PCP prophylaxis and its association with the GC dosage. Out of 1,460 patients, 21% underwent PCP prophylaxis. The frequency of prophylaxis decreased with a decrease in GC dosage. After adjusting for confounders, logistic regression revealed the odds ratio of PCP prophylaxis increased with higher prednisolone (PSL) doses: 3.7 for 5 ≤ PSL < 7.5 mg, 5.2 for 7.5 ≤ PSL < 10 mg, 9.0 for 10 ≤ PSL < 20 mg, and 43.1 for PSL ≥ 20 mg, using PSL < 5 mg as the reference. Decision tree analysis indicated that a PSL dosage of < 11 mg/day and immunosuppressant use were key determinants of PCP prophylaxis. This study provides valuable insights into PCP prophylaxis practices in patients with SLE in Japan, underscoring the importance of GC dosage and concomitant immunosuppressant use.
肺孢子虫肺炎(PCP)是因系统性红斑狼疮(SLE)等自身免疫性疾病而接受糖皮质激素(GC)等免疫抑制治疗的患者的一种机会性感染。尽管预防五氯苯酚的有效性已得到证实,但其临床应用,尤其是与糖皮质激素用量的结合仍不明确。我们旨在描述日本系统性红斑狼疮患者预防五氯苯酚的临床实践,评估 GC 剂量与预防五氯苯酚之间的关系,并探索与预防五氯苯酚相关的实践模式。这项横断面研究使用了日本全国机构狼疮登记处2016年至2021年的数据,纳入了确诊为系统性红斑狼疮的患者。通过描述性统计、多变量分析和决策树分析,我们研究了预防五氯苯酚的患病率及其与 GC 剂量的关系。在 1,460 名患者中,21% 的患者接受了五氯苯酚预防治疗。预防性治疗的频率随着 GC 剂量的减少而降低。在对混杂因素进行调整后,逻辑回归显示,泼尼松龙(PSL)剂量越大,预防五氯苯酚的几率比越高:以 PSL < 5 mg 为参照,5 ≤ PSL < 7.5 mg 为 3.7,7.5 ≤ PSL < 10 mg 为 5.2,10 ≤ PSL < 20 mg 为 9.0,PSL ≥ 20 mg 为 43.1。决策树分析表明,PSL用量< 11毫克/天和使用免疫抑制剂是预防PCP的关键决定因素。这项研究为日本系统性红斑狼疮患者预防五氯苯酚的实践提供了宝贵的见解,强调了GC剂量和同时使用免疫抑制剂的重要性。
{"title":"Clinical practice pattern of Pneumocystis pneumonia prophylaxis in systemic lupus erythematosus: a cross-sectional study from lupus registry of nationwide institutions (LUNA)","authors":"Takahisa Onishi, Ken-ei Sada, Keigo Hayashi, Yoshia Miyawaki, Ryusuke Yoshimi, Yasuhiro Shimojima, Shigeru Ohno, Hiroshi Kajiyama, Kunihiro Ichinose, Shuzo Sato, Michio Fujiwara, Nobuyuki Yajima, Takashi Kida, Yusuke Matsuo, Keisuke Nishimura, Takashi Yamane","doi":"10.1186/s13075-024-03434-2","DOIUrl":"https://doi.org/10.1186/s13075-024-03434-2","url":null,"abstract":"Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection in patients undergoing immunosuppressive therapy, such as glucocorticoid (GC) medication, for systemic autoimmune diseases like systemic lupus erythematosus (SLE). Despite the confirmed effectiveness of PCP prophylaxis, its clinical administration, especially in conjunction with GC dosage, remains unclear. We aimed to describe the clinical practice of PCP prophylaxis in association with SLE in Japan, evaluate the relationship between GC dosage and PCP prophylaxis, and explore the practice patterns associated with PCP prophylaxis. This cross-sectional study used data from the Lupus Registry of Nationwide Institutions in Japan from 2016 to 2021 and included patients diagnosed with SLE. Using descriptive statistics, multivariate analysis, and decision tree analysis, we examined the prevalence of PCP prophylaxis and its association with the GC dosage. Out of 1,460 patients, 21% underwent PCP prophylaxis. The frequency of prophylaxis decreased with a decrease in GC dosage. After adjusting for confounders, logistic regression revealed the odds ratio of PCP prophylaxis increased with higher prednisolone (PSL) doses: 3.7 for 5 ≤ PSL < 7.5 mg, 5.2 for 7.5 ≤ PSL < 10 mg, 9.0 for 10 ≤ PSL < 20 mg, and 43.1 for PSL ≥ 20 mg, using PSL < 5 mg as the reference. Decision tree analysis indicated that a PSL dosage of < 11 mg/day and immunosuppressant use were key determinants of PCP prophylaxis. This study provides valuable insights into PCP prophylaxis practices in patients with SLE in Japan, underscoring the importance of GC dosage and concomitant immunosuppressant use.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"10 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigation of GPM6B as a novel therapeutic target in Osteoarthritis 将 GPM6B 作为骨关节炎新治疗靶点的研究
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-12 DOI: 10.1186/s13075-024-03430-6
Chongyang Feng, Lin Liu, Jinxue Zhang, Linxiao Wang, Ke Lv, Hongbo Li, Yong Ding
Osteoarthritis (OA) is the most common motor system disease in older people, characterized by a high incidence and significant social and economic burden. Women have a higher risk of OA, more severe clinical symptoms, and a higher rate of disabilities than men. However, the pathogenesis of OA remains unclear. Therefore, we screened for differentially expressed genes (DEGs) in OA patients of different sex and searched for new targets that may be involved in regulating the development of OA. The study compared the expression of DEGs in synovial fluid exosomes between male and female patients with OA through RNA sequencing combined with bioinformatics analysis using public data. To evaluate the screened DEGs, synovial tissue and fluid samples were obtained from patients with OA who underwent joint replacement surgery. SiRNA-mediated knockdown in vitro experiments were performed to investigate the role of glycoprotein membrane 6B (GPM6B). Meanwhile, GPM6B gene knockout mice were used to assess the in vivo pathological roles of GPM6B in OA. The results revealed that GPM6B is a potential target associated with OA. Immunofluorescence staining demonstrated that GPM6B was expressed in fibroblast-like synoviocytes (FLS) and macrophage-like synoviocytes in patients with OA. In vitro experiments confirmed that GPM6B knockdown can reduce the expression of inflammatory factors in primary FLS from patients with OA. Under inflammatory conditions, GPM6B knockdown can reduce the expression of matrix metalloproteinases as well as proliferation of FLS. In addition, using a destabilization of the medial meniscus-induced OA model, we revealed that GPM6B is associated with OA progression in mice. Thus, we provided evidence that GPM6B act as a new target associated with OA.
骨关节炎(OA)是老年人最常见的运动系统疾病,具有发病率高、社会和经济负担重的特点。与男性相比,女性患 OA 的风险更高,临床症状更严重,致残率也更高。然而,OA 的发病机制仍不清楚。因此,我们筛选了不同性别 OA 患者的差异表达基因(DEGs),并寻找可能参与调控 OA 发病的新靶点。本研究通过RNA测序结合生物信息学分析,利用公开数据比较了男性和女性OA患者滑膜液外泌体中DEGs的表达情况。为了评估筛选出的 DEGs,研究人员从接受关节置换手术的 OA 患者身上采集了滑膜组织和滑膜液样本。通过 SiRNA 介导的体外敲除实验研究糖蛋白膜 6B(GPM6B)的作用。同时,利用 GPM6B 基因敲除小鼠评估 GPM6B 在 OA 中的体内病理作用。结果显示,GPM6B是与OA相关的潜在靶点。免疫荧光染色显示,GPM6B 在 OA 患者的成纤维细胞样滑膜细胞(FLS)和巨噬细胞样滑膜细胞中均有表达。体外实验证实,敲除 GPM6B 可减少 OA 患者原代 FLS 中炎症因子的表达。在炎症条件下,GPM6B 基因敲除可减少基质金属蛋白酶的表达以及 FLS 的增殖。此外,我们利用内侧半月板失稳诱导的 OA 模型,发现 GPM6B 与小鼠 OA 的进展有关。因此,我们为 GPM6B 成为与 OA 相关的新靶点提供了证据。
{"title":"Investigation of GPM6B as a novel therapeutic target in Osteoarthritis","authors":"Chongyang Feng, Lin Liu, Jinxue Zhang, Linxiao Wang, Ke Lv, Hongbo Li, Yong Ding","doi":"10.1186/s13075-024-03430-6","DOIUrl":"https://doi.org/10.1186/s13075-024-03430-6","url":null,"abstract":"Osteoarthritis (OA) is the most common motor system disease in older people, characterized by a high incidence and significant social and economic burden. Women have a higher risk of OA, more severe clinical symptoms, and a higher rate of disabilities than men. However, the pathogenesis of OA remains unclear. Therefore, we screened for differentially expressed genes (DEGs) in OA patients of different sex and searched for new targets that may be involved in regulating the development of OA. The study compared the expression of DEGs in synovial fluid exosomes between male and female patients with OA through RNA sequencing combined with bioinformatics analysis using public data. To evaluate the screened DEGs, synovial tissue and fluid samples were obtained from patients with OA who underwent joint replacement surgery. SiRNA-mediated knockdown in vitro experiments were performed to investigate the role of glycoprotein membrane 6B (GPM6B). Meanwhile, GPM6B gene knockout mice were used to assess the in vivo pathological roles of GPM6B in OA. The results revealed that GPM6B is a potential target associated with OA. Immunofluorescence staining demonstrated that GPM6B was expressed in fibroblast-like synoviocytes (FLS) and macrophage-like synoviocytes in patients with OA. In vitro experiments confirmed that GPM6B knockdown can reduce the expression of inflammatory factors in primary FLS from patients with OA. Under inflammatory conditions, GPM6B knockdown can reduce the expression of matrix metalloproteinases as well as proliferation of FLS. In addition, using a destabilization of the medial meniscus-induced OA model, we revealed that GPM6B is associated with OA progression in mice. Thus, we provided evidence that GPM6B act as a new target associated with OA.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"41 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142599751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis 成人和青少年皮肌炎血清蛋白质组学揭示的中性粒细胞和单核白细胞通路及上游调节因子
IF 4.9 2区 医学 Q1 Medicine Pub Date : 2024-11-11 DOI: 10.1186/s13075-024-03421-7
A. Clare Sparling, James M. Ward, Kakali Sarkar, Adam Schiffenbauer, Payam Noroozi Farhadi, Michael A. Smith, Saifur Rahman, Kamelia Zerrouki, Frederick W. Miller, Jian-Liang Li, Kerry A. Casey, Lisa G. Rider
Serum protein abundance was assessed in adult and juvenile dermatomyositis (DM and JDM) patients to determine differentially regulated proteins, altered pathways, and candidate disease activity biomarkers. Serum protein expression from 17 active adult DM and JDM patients each was compared to matched, healthy control subjects by a multiplex immunoassay. Pathway analysis and protein clustering of the differentially regulated proteins were examined to assess underlying mechanisms. Candidate disease activity biomarkers were identified by correlating protein expression with disease activity measures. Seventy-eight of 172 proteins were differentially expressed in the sera of DM and JDM patients compared to healthy controls. Forty-eight proteins were differentially expressed in DM, 32 proteins in JDM, and 14 proteins in both DM and JDM. Twelve additional differentially expressed proteins were identified after combining the DM and JDM cohorts. C-X-C motif chemokine ligand 10 (CXCL10) was the most strongly upregulated protein in both DM and JDM sera. Other highly upregulated proteins in DM included S100 calcium binding protein A12 (S100A12), CXCL9, and nicotinamide phosphoribosyltransferase (NAMPT), while highly upregulated proteins in JDM included matrix metallopeptidase 3 (MMP3), growth differentiation factor 15 (GDF15), and von Willebrand factor (vWF). Pathway analysis indicated that phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and toll-like receptor 7 (TLR7) signaling were activated in DM and JDM. Additional pathways specific to DM or JDM were identified. A protein cluster associated with neutrophils and mononuclear leukocytes and a cluster of interferon-associated proteins were observed in both DM and JDM. Twenty-two proteins in DM and 24 proteins in JDM sera correlated with global, muscle, and/or skin disease activity. Seven proteins correlated with disease activity measures in both DM and JDM sera. IL-1 receptor like 1 (IL1RL1) emerged as a candidate global disease activity biomarker in DM and JDM. Coordinate analysis of protein expression in DM and JDM patient sera by a multiplex immunoassay validated previous gene expression studies and identified novel dysregulated proteins, altered signaling pathways, and candidate disease activity biomarkers. These findings may further inform the assessment of DM and JDM patients and aid in the identification of potential therapeutic targets.
对成人皮肌炎和幼年皮肌炎(DM 和 JDM)患者的血清蛋白丰度进行了评估,以确定不同调控蛋白、改变的通路和候选疾病活动生物标记物。通过多重免疫测定法,将17名活跃的成年DM和JDM患者的血清蛋白表达与匹配的健康对照组进行了比较。对不同调控蛋白的通路分析和蛋白聚类进行了研究,以评估其潜在机制。通过将蛋白质表达与疾病活动指标相关联,确定了候选疾病活动生物标志物。与健康对照组相比,172 种蛋白质中有 78 种在 DM 和 JDM 患者的血清中表达不同。其中48个蛋白质在DM患者血清中有差异表达,32个蛋白质在JDM患者血清中有差异表达,14个蛋白质在DM和JDM患者血清中均有差异表达。将 DM 和 JDM 组群合并后,又发现了 12 种不同表达的蛋白质。C-X-C motif趋化因子配体10(CXCL10)是DM和JDM血清中上调最强烈的蛋白质。其他在DM中高调的蛋白质包括S100钙结合蛋白A12(S100A12)、CXCL9和烟酰胺磷酸核糖转移酶(NAMPT),而在JDM中高调的蛋白质包括基质金属肽酶3(MMP3)、生长分化因子15(GDF15)和von Willebrand因子(vWF)。通路分析表明,磷酸肌醇3-激酶(PI3K)、p38丝裂原活化蛋白激酶(MAPK)和toll样受体7(TLR7)信号在DM和JDM中被激活。此外,还发现了 DM 或 JDM 特有的其他通路。在 DM 和 JDM 中都观察到了与中性粒细胞和单核白细胞相关的蛋白质集群以及干扰素相关蛋白质集群。DM血清中的22种蛋白质和JDM血清中的24种蛋白质与全身、肌肉和/或皮肤疾病活动相关。在 DM 和 JDM 血清中,有 7 种蛋白质与疾病活动度相关。IL-1受体样1(IL1RL1)成为DM和JDM中候选的整体疾病活动性生物标志物。通过多重免疫测定对 DM 和 JDM 患者血清中蛋白质表达的协调分析验证了之前的基因表达研究,并确定了新的失调蛋白质、改变的信号通路和候选疾病活动生物标志物。这些发现可为 DM 和 JDM 患者的评估提供进一步信息,并有助于确定潜在的治疗目标。
{"title":"Neutrophil and mononuclear leukocyte pathways and upstream regulators revealed by serum proteomics of adult and juvenile dermatomyositis","authors":"A. Clare Sparling, James M. Ward, Kakali Sarkar, Adam Schiffenbauer, Payam Noroozi Farhadi, Michael A. Smith, Saifur Rahman, Kamelia Zerrouki, Frederick W. Miller, Jian-Liang Li, Kerry A. Casey, Lisa G. Rider","doi":"10.1186/s13075-024-03421-7","DOIUrl":"https://doi.org/10.1186/s13075-024-03421-7","url":null,"abstract":"Serum protein abundance was assessed in adult and juvenile dermatomyositis (DM and JDM) patients to determine differentially regulated proteins, altered pathways, and candidate disease activity biomarkers. Serum protein expression from 17 active adult DM and JDM patients each was compared to matched, healthy control subjects by a multiplex immunoassay. Pathway analysis and protein clustering of the differentially regulated proteins were examined to assess underlying mechanisms. Candidate disease activity biomarkers were identified by correlating protein expression with disease activity measures. Seventy-eight of 172 proteins were differentially expressed in the sera of DM and JDM patients compared to healthy controls. Forty-eight proteins were differentially expressed in DM, 32 proteins in JDM, and 14 proteins in both DM and JDM. Twelve additional differentially expressed proteins were identified after combining the DM and JDM cohorts. C-X-C motif chemokine ligand 10 (CXCL10) was the most strongly upregulated protein in both DM and JDM sera. Other highly upregulated proteins in DM included S100 calcium binding protein A12 (S100A12), CXCL9, and nicotinamide phosphoribosyltransferase (NAMPT), while highly upregulated proteins in JDM included matrix metallopeptidase 3 (MMP3), growth differentiation factor 15 (GDF15), and von Willebrand factor (vWF). Pathway analysis indicated that phosphoinositide 3-kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), and toll-like receptor 7 (TLR7) signaling were activated in DM and JDM. Additional pathways specific to DM or JDM were identified. A protein cluster associated with neutrophils and mononuclear leukocytes and a cluster of interferon-associated proteins were observed in both DM and JDM. Twenty-two proteins in DM and 24 proteins in JDM sera correlated with global, muscle, and/or skin disease activity. Seven proteins correlated with disease activity measures in both DM and JDM sera. IL-1 receptor like 1 (IL1RL1) emerged as a candidate global disease activity biomarker in DM and JDM. Coordinate analysis of protein expression in DM and JDM patient sera by a multiplex immunoassay validated previous gene expression studies and identified novel dysregulated proteins, altered signaling pathways, and candidate disease activity biomarkers. These findings may further inform the assessment of DM and JDM patients and aid in the identification of potential therapeutic targets.","PeriodicalId":8419,"journal":{"name":"Arthritis Research & Therapy","volume":"215 1","pages":""},"PeriodicalIF":4.9,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142598318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Arthritis Research & Therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1